1. Home
  2. BVN vs RNA Comparison

BVN vs RNA Comparison

Compare BVN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BVN
  • RNA
  • Stock Information
  • Founded
  • BVN 1953
  • RNA 2012
  • Country
  • BVN Peru
  • RNA United States
  • Employees
  • BVN N/A
  • RNA N/A
  • Industry
  • BVN Metal Mining
  • RNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BVN Basic Materials
  • RNA Health Care
  • Exchange
  • BVN Nasdaq
  • RNA Nasdaq
  • Market Cap
  • BVN 4.2B
  • RNA 4.0B
  • IPO Year
  • BVN 1996
  • RNA 2020
  • Fundamental
  • Price
  • BVN $17.49
  • RNA $37.34
  • Analyst Decision
  • BVN Buy
  • RNA Strong Buy
  • Analyst Count
  • BVN 2
  • RNA 14
  • Target Price
  • BVN $16.75
  • RNA $67.71
  • AVG Volume (30 Days)
  • BVN 805.4K
  • RNA 3.0M
  • Earning Date
  • BVN 07-24-2025
  • RNA 08-12-2025
  • Dividend Yield
  • BVN 1.67%
  • RNA N/A
  • EPS Growth
  • BVN 436.33
  • RNA N/A
  • EPS
  • BVN 1.98
  • RNA N/A
  • Revenue
  • BVN $1,307,905,000.00
  • RNA $8,927,000.00
  • Revenue This Year
  • BVN $14.24
  • RNA N/A
  • Revenue Next Year
  • BVN $9.63
  • RNA $196.18
  • P/E Ratio
  • BVN $8.55
  • RNA N/A
  • Revenue Growth
  • BVN 32.24
  • RNA N/A
  • 52 Week Low
  • BVN $11.50
  • RNA $21.51
  • 52 Week High
  • BVN $17.98
  • RNA $56.00
  • Technical
  • Relative Strength Index (RSI)
  • BVN 57.38
  • RNA 64.78
  • Support Level
  • BVN $16.90
  • RNA $35.49
  • Resistance Level
  • BVN $17.67
  • RNA $39.00
  • Average True Range (ATR)
  • BVN 0.54
  • RNA 1.92
  • MACD
  • BVN -0.04
  • RNA 0.31
  • Stochastic Oscillator
  • BVN 71.88
  • RNA 75.70

About BVN Buenaventura Mining Company Inc.

Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.

About RNA Avidity Biosciences Inc.

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Share on Social Networks: